Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Laura T. Morton"'
Autor:
Els P. van Hees, Laura T. Morton, Dennis F. G. Remst, Anne K. Wouters, Astrid Van den Eynde, J. H. Frederik Falkenburg, Mirjam H.M. Heemskerk
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundNK cells can be genetically engineered to express a transgenic T-cell receptor (TCR). This approach offers an alternative strategy to target heterogenous tumors, as NK:TCR cells can eradicate both tumor cells with high expression of HLA cla
Externí odkaz:
https://doaj.org/article/c42927c58d9f4959908c7bf19deb43e7
Autor:
Rosa A. van Amerongen, Laura T. Morton, Umesh G. Chaudhari, Dennis F.G. Remst, Renate S. Hagedoorn, Cathelijne W. van den Berg, Christian Freund, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 28, Iss , Pp 249-261 (2023)
The balance between safety and efficacy of T cell therapies remains challenging and T cell mediated toxicities have occurred. The stringent selection of tumor-specific targets and careful selection of tumor-specific T cells using T cell toxicity scre
Externí odkaz:
https://doaj.org/article/f9a7315aa021462c81fefd32e9e39fe4
Autor:
Miranda H Meeuwsen, Laura T Morton, Tassilo L A Wachsmann, Anne K Wouters, Dennis F G Remst, Marleen M van Loenen, J H Frederik Falkenburg, Mirjam H M Heemskerk
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background T cell receptor (TCR)-engineered cells can be powerful tools in the treatment of malignancies. However, tumor resistance by Human Leukocyte antigen (HLA) class I downregulation can negatively impact the success of any TCR-mediated cell the
Externí odkaz:
https://doaj.org/article/ee6aa46b6f7e4f30b82ef99125689149
Autor:
Mark Cobbold, David M. Langenau, Weiguo Lu, David R. Spriggs, Bo R. Rueda, Michael S. Lawrence, Eleanor Minogue, Mei Guo, Dominique T. Zarrella, Lauren R. Whelton, Eric Alpert, Sean Sepulveda, Laura T. Morton, Adam Langenbucher, James M. Heather, Qiqi Yang, David G. Millar, Chuan Yan, Songfa Zhang
Antibody–peptide epitope conjugates (APEC) are a new class of modified antibody–drug conjugates that redirect T-cell viral immunity against tumor cells. APECs contain a tumor-specific protease cleavage site linked to a patient-specific viral epit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79dbef811b4cd38494a2bce9ecdd065b
https://doi.org/10.1158/0008-5472.c.6513819
https://doi.org/10.1158/0008-5472.c.6513819
Autor:
Mark Cobbold, David M. Langenau, Weiguo Lu, David R. Spriggs, Bo R. Rueda, Michael S. Lawrence, Eleanor Minogue, Mei Guo, Dominique T. Zarrella, Lauren R. Whelton, Eric Alpert, Sean Sepulveda, Laura T. Morton, Adam Langenbucher, James M. Heather, Qiqi Yang, David G. Millar, Chuan Yan, Songfa Zhang
Supplementary Data from Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7495fc48d494f43cc3262f99c6257b6f
https://doi.org/10.1158/0008-5472.22431150
https://doi.org/10.1158/0008-5472.22431150
Autor:
Laura T Morton, Tassilo L A Wachsmann, Miranda H Meeuwsen, Anne K Wouters, Dennis F G Remst, Marleen M van Loenen, J H Frederik Falkenburg, Mirjam H M Heemskerk
Publikováno v:
Journal for ImmunoTherapy of Cancer, 10(3). BMJ PUBLISHING GROUP
BackgroundT cell receptor (TCR)-engineered cells can be powerful tools in the treatment of malignancies. However, tumor resistance by Human Leukocyte antigen (HLA) class I downregulation can negatively impact the success of any TCR-mediated cell ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2dd27fdd4e503533eb6c332b5faddfd
http://hdl.handle.net/1887/3566388
http://hdl.handle.net/1887/3566388
Autor:
Lieve E. van der Maarel, J.H. Frederik Falkenburg, Rob C. M. de Jong, Ilse Gille, Inge Jedema, Wesley Huisman, Derk Amsen, Lois Hageman, Laura T. Morton, Mirjam H.M. Heemskerk
Publikováno v:
Journal of infectious diseases, 226(5), 833-842. Oxford University Press
The Journal of Infectious Diseases, 226(5), 833-842. OXFORD UNIV PRESS INC
The Journal of Infectious Diseases, 226(5), 833-842. OXFORD UNIV PRESS INC
Background Adoptive transfer of genetically engineered T cells expressing antigen-specific T-cell receptors (TCRs) is an appealing therapeutic approach for Epstein-Barr virus (EBV)–associated malignancies of latency type II/III that express EBV ant
Autor:
Dirk M. van der Steen, Renate S. Hagedoorn, Michel G.D. Kester, Peter A. van Veelen, Mirjam H.M. Heemskerk, Lorenz Jahn, J.H. Frederik Falkenburg, Miranda H. Meeuwsen, Anne K. Wouters, Marieke Griffioen, Arnoud H. de Ru, Laura T. Morton, Dennis F.G. Remst, Christiaan Kweekel
Publikováno v:
Mol Ther
Molecular Therapy, 30(2), 564-578. CELL PRESS
Molecular Therapy, 30(2), 564-578. CELL PRESS
CAR T cell therapy has shown great promise for the treatment of B cell malignancies. However, antigen-negative escape variants often cause disease relapse, necessitating the development of multi-antigen-targeting approaches. We propose that a T cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc1481bbc9fed9ada4ccf84d4ea3ff3b
https://europepmc.org/articles/PMC8821929/
https://europepmc.org/articles/PMC8821929/
Autor:
Songfa Zhang, Chuan Yan, David G. Millar, Qiqi Yang, James M. Heather, Adam Langenbucher, Laura T. Morton, Sean Sepulveda, Eric Alpert, Lauren R. Whelton, Dominique T. Zarrella, Mei Guo, Eleanor Minogue, Michael S. Lawrence, Bo R. Rueda, David R. Spriggs, Weiguo Lu, David M. Langenau, Mark Cobbold
Publikováno v:
Cancer research. 82(5)
Antibody–peptide epitope conjugates (APEC) are a new class of modified antibody–drug conjugates that redirect T-cell viral immunity against tumor cells. APECs contain a tumor-specific protease cleavage site linked to a patient-specific viral epit
Autor:
Mirjam H.M. Heemskerk, Anne K. Wouters, Tassilo L. A. Wachsmann, J.H. Frederik Falkenburg, Miranda H. Meeuwsen, Dennis F. Remst, Laura T. Morton, Marleen M. van Loenen
TCR-engineered cells can be powerful tools in the treatment of malignancies. However tumor-resistance by HLA-class I downregulation can negatively-impact the success of any TCR-mediated cell therapy. Allogeneic NK-cells have demonstrated efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3063d07faa1b9600d072da4fa645e09
https://doi.org/10.21203/rs.3.rs-145130/v1
https://doi.org/10.21203/rs.3.rs-145130/v1